Xerclear® (Zoviduo®)

  • Mechanism

    Hydrocortisone and aciclovir combination

  • Disease areas

    Labial herpes

Xerclear® - Treatment of labial herpes (cold sores)

In 2009, Xerclear® (Zoviduo®) was approved for the treatment of labial herpes. The marketing rights to Xerclear® in the USA, Canada and Mexico were divested in 2010. The corresponding rights in Europe and the rest of the world have been outlicensed to Glaxo­SmithKline, with the exception of China, where Medivir has outlicensed the rights to Shijiazhuang Yuanmai Biotechnology Co Ltd. (SYB), and Israel and South America where Medivir has retained the rights.

project-icon-03.svg

Partners

GlaxoSmithKline

Shijiazhuang Yuanmai Biotechnology Co Ltd.

project-icon-04.svg

Project Status and Medivir participation

Medivir receives royalties on sales of ­Xerclear®­/­(Zoviduo®) from GlaxoSmithKline. In addition, Medivir would receive milestones when Zoviduo® is approved as an over the counter product in certain new markets.

After market registration and production in China, Medivir will receive a fixed royalty from SYB for each unit sold and the agreement guarantees a minimum sale during the first three years on the market amounting to single-digit million amounts in SEK.

Projects from our team

MIV-818

Nucleotide DNA polymerase inhibitor (oral)

Remetinostat

HDAC inhibitor (topical)

MIV-711

Cathepsin K inhibitor (oral)